Evidence map›Paper›PMID 41710011›Full record

ArticleRespirology case reports2026

Significant but Temporary Efficacy of Statin for a Patient With Severe Autoimmune Pulmonary Alveolar Proteinosis: A Case Report.

Fumihiko Makino, Kohei Shibayama, Yuki Muto, Rie Hayakawa, Kenta Izumi, Yohei Suzuki, Osamu Nagashima, Shinichi Sasaki, Kazuhisa Takahashi

Abstract read
In one paragraph

Article in Respirology case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Fumihiko MakinoDepartment of Respiratory Medicine Juntendo University Urayasu Hospital Chiba Japan.ORCID https://orcid.org/0009-0009-4476-9851
Kohei ShibayamaDepartment of Respiratory Medicine Juntendo University Urayasu Hospital Chiba Japan.
Yuki MutoDepartment of Respiratory Medicine Juntendo University Urayasu Hospital Chiba Japan.
Rie HayakawaDepartment of Respiratory Medicine Juntendo University Urayasu Hospital Chiba Japan.
Kenta IzumiDepartment of Respiratory Medicine Juntendo University Urayasu Hospital Chiba Japan.
Yohei SuzukiDepartment of Respiratory Medicine Juntendo University Urayasu Hospital Chiba Japan.
Osamu NagashimaDepartment of Respiratory Medicine Juntendo University Urayasu Hospital Chiba Japan.
Shinichi SasakiDepartment of Respiratory Medicine Juntendo University Urayasu Hospital Chiba Japan.ORCID https://orcid.org/0000-0002-2257-7658
Kazuhisa TakahashiDepartment of Respiratory Medicine Faculty of Medicine and Graduate School of Medicine, Juntendo University Tokyo Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Autoimmune pulmonary alveolar proteinosis (APAP) is a rare autoimmune lung disorder characterised by the presence of anti-granulocyte-macrophage colony-stimulating factor (GM-CSF) antibodies. Whole-lung lavage (WLL) therapy remains the standard treatment for severe cases. Recently, inhaled GM-CSF therapy has been approved in Japan; however, the cost of the treatment remains a limiting factor. Several reports have suggested that oral statin therapy may be a promising therapeutic option for APAP. Herein, we report a case of severe APAP that underwent WLL therapy twice and achieved an excellent response and remarkable clinical resolution of respiratory failure after the initiation of oral statin therapy. Remarkable improvements in oxygen saturation, blood gas analysis, serum biomarker levels and pulmonary function test results were observed after statin administration. However, the efficacy was temporary, and respiratory failure relapsed 2 years after the initiation of statin therapy. Statin therapy for APAP was deemed effective but potentially temporary.

Indexed as

anti‐GM‐CSF antibodyautoimmune pulmonary alveolar proteinosisdyslipidaemiafoamy alveolar macrophagesoral statin therapy

Identifiers

PMID41710011
PMCPMC12910239

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.